Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Deramiocel Biologics License Application (BLA) under active FDA reviewHOPE-3 Phase 3 results published in The Lancet; primary endpoint of upper limb function achieved at p=0.029Cash, cash equivalents and marketable